Nominated candidates entering clinical development often have sub-optimal physicochemical, biopharmaceutic or DMPK properties for oral delivery. Development teams are challenged with how to understand the properties of new drug candidates, how to design the appropriate formulation strategy and how to move quickly and successfully into early phase clinical trials. Along the way, it is important to identify developability risks and take steps to mitigate these factors, balanced carefully against time and cost investments.
This webinar discusses effective strategies being used by biotech and pharmaceutical companies to overcome biopharmaceutic challenges for small molecules in today’s drug development pipeline; and explores alternative approaches for accelerating your early development plan.
Learn about case studies relating to:
• Poor solubility molecules
• Drugs with short half-lives
• Preclinical to clinical translation
Chris Roe, Senior Research Fellow , Quotient Sciences
Dr Shriram Pathak, Senior Research Fellow, Quotient Sciences